Unique ID issued by UMIN | UMIN000007176 |
---|---|
Receipt number | R000003482 |
Scientific Title | Clinical study of Sublingal immunotherapy with Lactobacillus strain for patients with Japanese cedar pollinosis : A Randomized Single Blind Placebo-Controlled Trial Single Blind Test |
Date of disclosure of the study information | 2012/01/31 |
Last modified on | 2012/01/31 13:55:00 |
Clinical study of Sublingal immunotherapy with Lactobacillus strain for patients with Japanese cedar pollinosis : A Randomized Single Blind Placebo-Controlled Trial
Single Blind Test
Lactobacillus strain Th1 adjuvant for sublingal allergy vaccine
Clinical study of Sublingal immunotherapy with Lactobacillus strain for patients with Japanese cedar pollinosis : A Randomized Single Blind Placebo-Controlled Trial
Single Blind Test
Lactobacillus strain Th1 adjuvant for sublingal allergy vaccine
Japan |
Japanese cedar pollen allergy
Oto-rhino-laryngology |
Others
NO
To Study the efficacy and safety of Lactobacillus strain(LAB) Th1 adjuvant for the sublingal immunotherapy(SLIT) of patients with Japanese cedar pollinosis.
Safety,Efficacy
Confirmatory
Pragmatic
Phase III
Symptom-medication score
Local findings in rhinoscope
Serum anti-Japanese cedar pollen specific IgE antibody
Serum ECP level
Lymphocyte Subsets of Peripheral Blood Mononuclear Cell (Immunophenotyping)
Interventional
Parallel
Randomized
Individual
Single blind -participants are blinded
Placebo
NO
NO
Institution is considered as a block.
NO
Central registration
4
Treatment
Medicine | Food |
From December 2009 to May 2010, patients of control 1 receive active treatment and 1 LAB tablet at 7 times per week. The induction/build-up phase is 3 weeks, with an increasing daliy number of the extract drops at three consentrations.
From December 2009 to May 2010, patients of control 1 receive active treatment and 1 placebo tablet at 7 times per week. The induction/build-up phase is 3 weeks, with an increasing daliy number of the extract drops at three consentrations.
From December 2009 to May 2010, patients of control 2 receive and 1 LAB tablet at 7 times per week.The induction/build-up phase is 3 weeks,with an increasing daliy number of the placebo drops as control 1.
From December 2009 to May 2010, patients of control 2 receive and 1 placebo tablet at 7 times per week.The induction/build-up phase is 3 weeks,with an increasing daliy number of the placebo drops as control 1.
20 | years-old | <= |
65 | years-old | >= |
Male and Female
1)Clinical history of cedar pollen-induced allergic rhinoconjunctivitis for at least 2 years
2)Positive specific IgE to cry j1/2 antigen(CAP-RAST>=class2)
1)The history of severe asthma
2)The history of anti-allergic drugs within 4 weeks
3)Perior history of immunotherapy with cedar pollen
4)Pregnant women and those at risk of pregnancy
5)Complication of the other nasal-paranasal disease
300
1st name | |
Middle name | |
Last name | Yoshitaka Okamoto |
Chiba University Graduate School
Department of Otorhinolaryngology
1-8-1 Inohana,Chuo-ku Chiba 260-8677
043-226-2137
1st name | |
Middle name | |
Last name | Shigetoshi Horiguchi |
Graduate School of Medicine, Chiba University
Department of Otolaryngology
1-8-1 Inohana,Chuo-ku, Chiba, 260-8677
043-226-2137
http://orl-web2.m.chiba-u.jp/
jibika@office.chiba-u.jp
Dept. of Otolaryngology, Graduate School of Medicine,
Chiba University
Ministry of Health, Labour and Welfare
NO
2012 | Year | 01 | Month | 31 | Day |
Unpublished
Completed
2009 | Year | 11 | Month | 04 | Day |
2009 | Year | 11 | Month | 01 | Day |
2012 | Year | 01 | Month | 31 | Day |
2012 | Year | 01 | Month | 31 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003482